{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:28:12Z","timestamp":1791919692252,"version":"4.3.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014269","name":"Uniwersytet Medyczny w Bia\u0142ymstoku","doi-asserted-by":"publisher","award":["SUB\/2\/DN\/22\/004\/2213"],"award-info":[{"award-number":["SUB\/2\/DN\/22\/004\/2213"]}],"id":[{"id":"10.13039\/501100014269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polypharmacology is an emerging strategy of design, synthesis, and clinical implementation of pharmaceutical agents that act on multiple targets simultaneously. It should not be mixed up with polytherapy, which is based on the use of multiple selective drugs and is considered a cornerstone of current clinical practice. However, this \u2018classic\u2019 approach, when facing urgent medical challenges, such as multifactorial diseases, increasing resistance to pharmacotherapy, and multimorbidity, seems to be insufficient. The \u2018novel\u2019 polypharmacology concept leads to a more predictable pharmacokinetic profile of multi-target-directed ligands (MTDLs), giving a chance to avoid drug-drug interactions and improve patient compliance due to the simplification of dosing regimens. Plenty of recently marketed drugs interact with multiple biological targets or disease pathways. Many offer a significant additional benefit compared to the standard treatment regimens. In this paper, we will briefly outline the genesis of polypharmacology and its differences to polytherapy. We will also present leading concepts for obtaining MTDLs. Subsequently, we will describe some successfully marketed drugs, the mechanisms of action of which are based on the interaction with multiple targets. To get an idea, of whether MTDLs are indeed important in contemporary pharmacology, we also carefully analyzed drugs approved in 2022 in Germany: 10 out of them were found multi-targeting, including 7 antitumor agents, 1 antidepressant, 1 hypnotic, and 1 drug indicated for eye disease.<\/jats:p>","DOI":"10.1007\/s43440-023-00501-4","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T18:56:19Z","timestamp":1686077779000},"page":"755-770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Polypharmacology: promises and new drugs in 2022"],"prefix":"10.1007","volume":"75","author":[{"given":"Piotr","family":"Ryszkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7057-8153","authenticated-orcid":false,"given":"Barbara","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7708-6998","authenticated-orcid":false,"given":"Eberhard","family":"Schlicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"501_CR1","unstructured":"World Health Organization. Medication safety in polypharmacy. 2019;1\u201363. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325454\/WHO-UHC-SDS-2019.11-eng.pdf?sequence=1&isAllowed=y. Accessed 19 April 2023."},{"key":"501_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.655364","volume":"12","author":"P Kardas","year":"2021","unstructured":"Kardas P, Urba\u0144ski F, Lichwierowicz A, Chudzy\u0144ska E, Kardas G, Czech M. Prevalence and age structure of polypharmacy in Poland: results of the analysis of the national real-world database of 38 million citizens. Front Pharmacol. 2021;12: 655364.","journal-title":"Front Pharmacol"},{"issue":"1","key":"501_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.","journal-title":"BMC Geriatr"},{"issue":"3","key":"501_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s41999-021-00479-3","volume":"12","author":"F Pazan","year":"2021","unstructured":"Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443\u201352.","journal-title":"Eur Geriatr Med"},{"issue":"3","key":"501_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/jm7009364","volume":"51","author":"A Cavalli","year":"2008","unstructured":"Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008;51(3):347\u201372.","journal-title":"J Med Chem"},{"issue":"19","key":"501_CR6","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1021\/jm5006463","volume":"57","author":"A Anighoro","year":"2014","unstructured":"Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57(19):7874\u201387.","journal-title":"J Med Chem"},{"issue":"2","key":"501_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","volume":"62","author":"E Proschak","year":"2019","unstructured":"Proschak E, Stark H, Merk D. Polypharmacology by design: a medicinal chemist\u2019s perspective on multitargeting compounds. J Med Chem. 2019;62(2):420\u201344.","journal-title":"J Med Chem"},{"issue":"9","key":"501_CR8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/17460441.2020.1767063","volume":"15","author":"R Chaudhari","year":"2020","unstructured":"Chaudhari R, Fong LW, Tan Z, Huang B, Zhang S. An up-to-date overview of computational polypharmacology in modern drug discovery. Expert Opin Drug Discov. 2020;15(9):1025\u201344.","journal-title":"Expert Opin Drug Discov"},{"key":"501_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.106055","volume":"176","author":"A Kabir","year":"2022","unstructured":"Kabir A, Muth A. Polypharmacology: the science of multi-targeting molecules. Pharmacol Res. 2022;176: 106055.","journal-title":"Pharmacol Res"},{"issue":"5","key":"501_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2174\/1568026623666230126112628","volume":"23","author":"MT Scotti","year":"2023","unstructured":"Scotti MT, Scotti L. Challenges and discoveries in polypharmacology. Curr Top Med Chem. 2023;23(5):331\u20133.","journal-title":"Curr Top Med Chem"},{"key":"501_CR11","unstructured":"National Library of Medicine. Definition of polypharmacology. https:\/\/www.ncbi.nlm.nih.gov\/mesh\/?term=polypharmacology. Accessed 19 April 2023."},{"issue":"15","key":"501_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","volume":"9","author":"R Morphy","year":"2004","unstructured":"Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today. 2004;9(15):641\u201351.","journal-title":"Drug Discov Today"},{"issue":"3","key":"501_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/cells11030471","volume":"11","author":"A Papa","year":"2022","unstructured":"Papa A, Pasquini S, Contri C, Gemma S, Campiani G, Butini S, et al. Polypharmacological approaches for CNS diseases: focus on endocannabinoid degradation inhibition. Cells. 2022;11(3):471.","journal-title":"Cells"},{"key":"501_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.952192","volume":"13","author":"M Alegr\u00eda-Arcos","year":"2022","unstructured":"Alegr\u00eda-Arcos M, Barbosa T, Sep\u00falveda F, Combariza G, Gonz\u00e1lez J, Gil C, et al. Network pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19. Front Pharmacol. 2022;13: 952192.","journal-title":"Front Pharmacol"},{"issue":"2","key":"501_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3390\/molecules28020825","volume":"28","author":"A Lamens","year":"2023","unstructured":"Lamens A, Bajorath J. Explaining accurate predictions of multitarget compounds with machine learning models derived for individual targets. Molecules. 2023;28(2):825.","journal-title":"Molecules"},{"issue":"5","key":"501_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2174\/1568026623666230126112628","volume":"23","author":"TCM Lustoza Rodrigues","year":"2023","unstructured":"Lustoza Rodrigues TCM, de Sousa NF, Dos Santos AMF, Aires Guimar\u00e3es RD, Scotti MT, Scotti L. Challenges and discoveries in polypharmacology of neurodegenerative diseases. Curr Top Med Chem. 2023;23(5):349\u201370.","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"501_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/med.20248","volume":"33","author":"R Le\u00f3n","year":"2013","unstructured":"Le\u00f3n R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer\u2019s disease. Med Res Rev. 2013;33(1):139\u201389.","journal-title":"Med Res Rev"},{"issue":"7","key":"501_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.tips.2020.04.008","volume":"41","author":"O Benek","year":"2020","unstructured":"Benek O, Korabecny J, Soukup O. A perspective on multi-target drugs for Alzheimer\u2019s disease. Trends Pharmacol Sci. 2020;41(7):434\u201345.","journal-title":"Trends Pharmacol Sci"},{"key":"501_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2022.116742","volume":"61","author":"N Kumar","year":"2022","unstructured":"Kumar N, Kumar V, Anand P, Kumar V, Ranjan Dwivedi A, Kumar V. Advancements in the development of multi-target directed ligands for the treatment of Alzheimer\u2019s disease. Bioorg Med Chem. 2022;61: 116742.","journal-title":"Bioorg Med Chem"},{"key":"501_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.730257","volume":"12","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W. Single-target versus multi-target drugs versus combinations of drugs with multiple targets: preclinical and clinical evidence for the treatment or prevention of epilepsy. Front Pharmacol. 2021;12: 730257.","journal-title":"Front Pharmacol"},{"issue":"5","key":"501_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1568026623666230123142357","volume":"23","author":"S Nandi","year":"2023","unstructured":"Nandi S, Chauhan B, Tarannum H, Khede MK. Multi-target polypharmacology of 4-aminoquinoline compounds against malaria, tuberculosis and cancer. Curr Top Med Chem. 2023;23(5):403\u201314.","journal-title":"Curr Top Med Chem"},{"issue":"10","key":"501_CR22","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.34067\/KID.0003582021","volume":"2","author":"JD Imig","year":"2021","unstructured":"Imig JD, Merk D, Proschak E. Multi-target drugs for kidney diseases. Kidney360. 2021;2(10):1645\u201353.","journal-title":"Kidney360"},{"key":"501_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112931","volume":"209","author":"C Wetzel","year":"2021","unstructured":"Wetzel C, Lonneman M, Wu C. Polypharmacological drug actions of recently FDA approved antibiotics. Eur J Med Chem. 2021;209: 112931.","journal-title":"Eur J Med Chem"},{"key":"501_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.554961","volume":"11","author":"FF Lillich","year":"2021","unstructured":"Lillich FF, Imig JD, Proschak E. Multi-target approaches in metabolic syndrome. Front Pharmacol. 2021;11: 554961.","journal-title":"Front Pharmacol"},{"key":"501_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.967115","volume":"9","author":"Y Li","year":"2022","unstructured":"Li Y, Gao Y, Li G. Preclinical multi-target strategies for myocardial ischemia-reperfusion injury. Front Cardiovasc Med. 2022;9: 967115.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"501_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/17460441.2018.1413089","volume":"13","author":"B Ravikumar","year":"2018","unstructured":"Ravikumar B, Aittokallio T. Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery. Expert Opin Drug Discov. 2018;13(2):179\u201392.","journal-title":"Expert Opin Drug Discov"},{"issue":"7","key":"501_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/17460441.2022.2072827","volume":"17","author":"A Zi\u0119ba","year":"2022","unstructured":"Zi\u0119ba A, St\u0119pnicki P, Matosiuk D, Kaczor AA. What are the challenges with multi-targeted drug design for complex diseases? Expert Opin Drug Discov. 2022;17(7):673\u201383.","journal-title":"Expert Opin Drug Discov"},{"key":"501_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-pharmtox-010818-021511","volume":"59","author":"JGC van Hasselt","year":"2019","unstructured":"van Hasselt JGC, Iyengar R. Systems pharmacology: defining the interactions of drug combinations. Annu Rev Pharmacol Toxicol. 2019;59:21\u201340.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"501_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10741-021-10135-4","volume":"27","author":"J Beezer","year":"2022","unstructured":"Beezer J, Al Hatrushi M, Husband A, Kurdi A, Forsyth P. Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev. 2022;27(2):465\u201392.","journal-title":"Heart Fail Rev"},{"issue":"22","key":"501_CR30","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.1021\/jm400856t","volume":"56","author":"JU Peters","year":"2013","unstructured":"Peters JU. Polypharmacology-foe or friend? J Med Chem. 2013;56(22):8955\u201371.","journal-title":"J Med Chem"},{"issue":"3","key":"501_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17460441.2017.1280024","volume":"12","author":"R Chaudhari","year":"2017","unstructured":"Chaudhari R, Tan Z, Huang B, Zhang S. Computational polypharmacology: a new paradigm for drug discovery. Expert Opin Drug Discov. 2017;12(3):279\u201391.","journal-title":"Expert Opin Drug Discov"},{"issue":"3","key":"501_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/03007995.2023.2165812","volume":"39","author":"U Gottwald-Hostalek","year":"2023","unstructured":"Gottwald-Hostalek U, Sun N. Contribution of single-pill combinations in the management of hypertension: perspectives from China, Europe and the USA. Curr Med Res Opin. 2023;39(3):331\u201340.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"501_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11095-020-02847-3","volume":"37","author":"R Fern\u00e1ndez-Garc\u00eda","year":"2020","unstructured":"Fern\u00e1ndez-Garc\u00eda R, Prada M, Bol\u00e1s-Fern\u00e1ndez F, Ballesteros MP, Serrano DR. Oral fixed-dose combination pharmaceutical products: industrial manufacturing versus personalized 3D printing. Pharm Res. 2020;37(7):132.","journal-title":"Pharm Res"},{"issue":"2","key":"501_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/pharmaceutics15020313","volume":"15","author":"DR Serrano","year":"2023","unstructured":"Serrano DR, Kara A, Yuste I, Luciano FC, Ongoren B, Anaya BJ, et al. 3D printing technologies in personalized medicine, nanomedicines, and biopharmaceuticals. Pharmaceutics. 2023;15(2):313.","journal-title":"Pharmaceutics"},{"issue":"4","key":"501_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/bioengineering4040079","volume":"4","author":"AA Konta","year":"2017","unstructured":"Konta AA, Garc\u00eda-Pi\u00f1a M, Serrano DR. Personalised 3D printed medicines: which techniques and polymers are more successful? Bioengineering. 2017;4(4):79.","journal-title":"Bioengineering"},{"issue":"1","key":"501_CR36","doi-asserted-by":"publisher","first-page":"bbac621","DOI":"10.1093\/bib\/bbac621","volume":"24","author":"Y Luo","year":"2023","unstructured":"Luo Y, Wang P, Mou M, Zheng H, Hong J, Tao L, et al. A novel strategy for designing the magic shotguns for distantly related target pairs. Brief Bioinform. 2023;24(1):bbac621.","journal-title":"Brief Bioinform."},{"issue":"7","key":"501_CR37","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.pnpbp.2003.09.006","volume":"27","author":"HJ M\u00f6ller","year":"2003","unstructured":"M\u00f6ller HJ. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1101\u201311.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"501_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/ph14030238","volume":"14","author":"M Carli","year":"2021","unstructured":"Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, Aringhieri S, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals. 2021;14(3):238.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"501_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","volume":"68","author":"E Richelson","year":"2000","unstructured":"Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68(1):29\u201339.","journal-title":"Life Sci"},{"issue":"12","key":"501_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/minf.202200190","volume":"41","author":"C Feldmann","year":"2022","unstructured":"Feldmann C, Bajorath J. Advances in computational polypharmacology. Mol Inform. 2022;41(12): e2200190.","journal-title":"Mol Inform"},{"key":"501_CR41","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/msb.2013.10","volume":"9","author":"M Kuhn","year":"2013","unstructured":"Kuhn M, Al Banchaabouchi M, Campillos M, Jensen LJ, Gross C, Gavin AC, et al. Systematic identification of proteins that elicit drug side effects. Mol Syst Biol. 2013;9:663.","journal-title":"Mol Syst Biol"},{"key":"501_CR42","unstructured":"European Medicines Agency. Kadcyla\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kadcyla-epar-product-information_en.pdf. Accessed 19 April 2023."},{"issue":"1","key":"501_CR43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.25259\/IJDVL_191_20","volume":"87","author":"P Santhosh","year":"2021","unstructured":"Santhosh P, Thomas MH. Ozenoxacin: a novel topical antibiotic. Indian J Dermatol Venereol Leprol. 2021;87(1):131\u20134.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"8","key":"501_CR44","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40265-022-01725-z","volume":"82","author":"A Lee","year":"2022","unstructured":"Lee A, Lamb YN, Shirley M. Delafloxacin: a review in community-acquired pneumonia. Drugs. 2022;82(8):913\u201323.","journal-title":"Drugs"},{"key":"501_CR45","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.2147\/IDR.S205309","volume":"13","author":"DR Giacobbe","year":"2020","unstructured":"Giacobbe DR, Ciacco E, Girmenia C, Pea F, Rossolini GM, Sotgiu G, et al. Evaluating cefiderocol in the treatment of multidrug-resistant gram-negative bacilli: a review of the emerging data. Infect Drug Resist. 2020;13:4697\u2013711.","journal-title":"Infect Drug Resist"},{"key":"501_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106552","volume":"187","author":"R Roskoski Jr","year":"2023","unstructured":"Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update. Pharmacol Res. 2023;187: 106552.","journal-title":"Pharmacol Res"},{"issue":"6","key":"501_CR47","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2174\/0929867321666141216125528","volume":"22","author":"L Garuti","year":"2015","unstructured":"Garuti L, Roberti M, Bottegoni G. Multi-kinase inhibitors. Curr Med Chem. 2015;22(6):695\u2013712.","journal-title":"Curr Med Chem"},{"issue":"2","key":"501_CR48","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1634\/theoncologist.2014-0177","volume":"20","author":"K Tzogani","year":"2015","unstructured":"Tzogani K, Skibeli V, Westgaard I, Dalhus M, Thoresen H, Slot KB, et al. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2015;20(2):196\u2013201.","journal-title":"Oncologist"},{"key":"501_CR49","unstructured":"European Medicines Agency. Cabometyx\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cabometyx-epar-product-information_en.pdf. Accessed 19 April 2023."},{"key":"501_CR50","unstructured":"European Medicines Agency. Sutent\u00ae Summary of product characteristics. www.ema.europa.eu\/en\/documents\/product-information\/sutent-epar-product-information_en.pdf. Accessed 19 April 2023."},{"issue":"1","key":"501_CR51","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1634\/theoncologist.2015-0276","volume":"21","author":"I Gravanis","year":"2016","unstructured":"Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, et al. The European medicines agency review of brentuximab vedotin (Adcetris) for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2016;21(1):102\u20139.","journal-title":"Oncologist"},{"issue":"3","key":"501_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100497","volume":"7","author":"S Michaleas","year":"2022","unstructured":"Michaleas S, Moreno Oliver A, Mueller-Berghaus J, Sarac SB, van der Elst ME, M\u00fcller-Egert S, et al. The European medicines agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer. ESMO Open. 2022;7(3): 100497.","journal-title":"ESMO Open"},{"key":"501_CR53","unstructured":"Pharmazeutische Zeitung. Arzneistoffe, Jahrgang 2022 [Drugs introduced in 2022]. www.pharmazeutische-zeitung.de\/arzneistoffe\/arzneistoff-jahrgang\/jahr\/2022\/. Accessed 11 May 2023."},{"key":"501_CR54","doi-asserted-by":"publisher","first-page":"1070660","DOI":"10.3389\/fimmu.2022.1070660","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang Z, Zhou H, Xu J, Wang J, Niu T. Safety and efficacy of dual PI3K-\u03b4, \u03b3 inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: a systematic review and meta-analysis of prospective clinical trials. Front Immunol. 2023;13:1070660.","journal-title":"Front Immunol"},{"issue":"2","key":"501_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/17474124.2023.2167711","volume":"17","author":"A Sargsyan","year":"2023","unstructured":"Sargsyan A, Kucharczyk MA, Jones RL, Constantinidou A. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors. Expert Rev Gastroenterol Hepatol. 2023;17(2):119\u201327.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2","key":"501_CR56","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2174\/1871520622666220523145609","volume":"23","author":"K Billowria","year":"2023","unstructured":"Billowria K, Das Gupta G, Chawla PA. Amivantamab: a new hope in targeting non-small cell lung cancer. Anticancer Agents Med Chem. 2023;23(2):124\u201341.","journal-title":"Anticancer Agents Med Chem"},{"issue":"2","key":"501_CR57","first-page":"139","volume":"2","author":"P Tarantino","year":"2021","unstructured":"Tarantino P, Morganti S, Curigliano G. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Explor Target Antitumor Ther. 2021;2(2):139\u201355.","journal-title":"Explor Target Antitumor Ther"},{"key":"501_CR58","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2147\/OTT.S370900","volume":"15","author":"J Hoffman-Censits","year":"2022","unstructured":"Hoffman-Censits J, Maldonado L. Targeted treatment of locally advanced and metastatic urothelial cancer: Enfortumab vedotin in context. Onco Targets Ther. 2022;15:1519\u201329.","journal-title":"Onco Targets Ther"},{"issue":"11","key":"501_CR59","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang C. Mosunetuzumab: first approval. Drugs. 2022;82(11):1229\u201334. https:\/\/doi.org\/10.1007\/s40265-022-01749-5.","journal-title":"Drugs"},{"issue":"3","key":"501_CR60","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1358\/dot.2023.59.3.3542417","volume":"59","author":"Z Wang","year":"2023","unstructured":"Wang Z, Xie Y, Wang JQ, Cheng Y, Fleishman J, Chen ZS, et al. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma. Drugs Today (Barc). 2023;59(3):179\u201393.","journal-title":"Drugs Today (Barc)"},{"key":"501_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.931970","volume":"13","author":"A Couvineau","year":"2022","unstructured":"Couvineau A, Nicole P, Gratio V, Voisin T. The orexin receptors: Structural and anti-tumoral properties. Front Endocrinol. 2022;13: 931970.","journal-title":"Front Endocrinol"},{"issue":"5","key":"501_CR62","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","volume":"82","author":"A Markham","year":"2022","unstructured":"Markham A. Daridorexant: first approval. Drugs. 2022;82(5):601\u20137.","journal-title":"Drugs"},{"issue":"1","key":"501_CR63","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41380-022-01824-z","volume":"28","author":"T Kishi","year":"2023","unstructured":"Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, et al. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023;28(1):402\u20139.","journal-title":"Mol Psychiatry"},{"issue":"7","key":"501_CR64","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M. Faricimab: first approval. Drugs. 2022;82(7):825\u201330.","journal-title":"Drugs"},{"issue":"29\u201330","key":"501_CR65","first-page":"513","volume":"117","author":"A Stahl","year":"2020","unstructured":"Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020;117(29\u201330):513\u201320.","journal-title":"Dtsch Arztebl Int"},{"key":"501_CR66","unstructured":"Gemeinsamer Bundesausschuss. The benefit assessment of medicinal products in accordance with the German Social Code, Book Five. https:\/\/www.g-ba.de\/english\/benefitassessment\/. Accessed 19 April 2023."},{"key":"501_CR67","unstructured":"Gemeinsamer Bundesausschuss. Zusatznutzen neuer Arzneimittel - Kategorien [Additional benefits of new medicinal products - categories]. https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/nutzenbewertung-35a\/zusatznutzen\/. Accessed 19 April 2023."},{"key":"501_CR68","unstructured":"Gemeinsamer Bundesausschuss. Resolution of the federal joint committee on an amendment of the pharmaceuticals directive annex xii - benefit assessment of medicinal products with new active ingredients according to Section 35a SGB V: Ripretinib (gastrointestinal stromal tumours (GIST), \u2265 3 prior therapies). https:\/\/www.g-ba.de\/downloads\/39-1464-5469\/2022-06-16_AM-RL-XII_Ripretinib_D-782_EN.pdf. Accessed 19 April 2023."},{"key":"501_CR69","unstructured":"Gemeinsamer Bundesausschuss Resolution of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive: Annex XII - Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V Amivantamab (lung cancer, non-small cell, activating EGFR Exon 20 Insertion mutations, after platinum-based chemotherapy) https:\/\/www.g-ba.de\/downloads\/39-1464-5516\/2022-07-07_AM-RL-XII_Amivantamab_D-788_EN.pdf. Accessed 19 April 2023."},{"key":"501_CR70","unstructured":"vfa (Verband Forschender Arzneimittelhersteller). Die neuen Medikamente von 2022 [The new drugs introduced in 2022]. www.vfa.de\/de\/arzneimittel-forschung\/woran-wir-forschen\/neue-medikamente-und-anwendungsgebiete-2022. Accessed 11 May 2023."},{"key":"501_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2023.130909","volume":"448","author":"P Rodrigues","year":"2023","unstructured":"Rodrigues P, Guimar\u00e3es L, Carvalho AP, Oliva-Teles L. Carbamazepine, venlafaxine, tramadol, and their main metabolites: toxicological effects on zebrafish embryos and larvae. J Hazardous Mater. 2023;448: 130909.","journal-title":"J Hazardous Mater"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-023-00501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-023-00501-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-023-00501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T07:20:19Z","timestamp":1690442419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-023-00501-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["501"],"URL":"https:\/\/doi.org\/10.1007\/s43440-023-00501-4","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests. All authors read and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}